AROMICS receives 1 Million Euros to advance in its therapy for cancer

13/03/2019

Imagen Noticia

The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program,  a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposure. 

More info here.

European Union